Brief: Rallybio Reports Fourth Quarter And Full Year 2022 Financial Results

Rallybio

06/03/2023 13:20

March 6 (Reuters) - Rallybio Corp  RLYB.O :
    * RALLYBIO REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS
    * PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF RLYB116 CONTINUES
TO
PROGRESS; SAFETY, PK AND PD DATA EXPECTED IN 4Q 2023
    * 169.0 MILLION CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES
AS OF DECEMBER 31, 2022; PROVIDES RUNWAY INTO 1Q 2025
    * EXPECTS TO REPORT DATA FROM PHASE 1B CLINICAL STUDY OF
RLYB212
AT A SCIENTIFIC CONFERENCE IN 2023
    * QTRLY NET LOSS PER COMMON SHARE OF $0.46
    * AS OF DECEMBER 31, 2022, CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES WERE $169.0 MILLION
    * Q4 EARNINGS PER SHARE VIEW $-0.60 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw6H0Glwa 
Further company coverage:  RLYB.O 

 ((Reuters.Briefs@thomsonreuters.com;))